Proteostasis Ther Cmn (NASDAQ:PTI) shares traded -3.67% down during most recent session to reach at the closing price of $1.05. The stock exchanged hands 1.09 Million shares versus average trading capacity of 1.97 Million shares, yielding a market cap of $55.1 Million. Wall Street analysts covering the stock are projecting that the stock will reach $10.6 within the next 52-weeks. The mean target projections are based on 5 opinions.

Taking a broader look brokerage firms’ analysts on the street with an expectant view have Proteostasis Ther Cmn (NASDAQ:PTI) high price target of $15 and with a conservative view have low price target of $5.

“Initiates Coverage On” Proteostasis Ther Cmn (NASDAQ:PTI) in a research note issued to investors on 11/07/18 to Overweight with price target of $21.

Additionally on 10/29/18 “Initiates Coverage On” Proteostasis Ther Cmn (NASDAQ:PTI) to Overweight setting price target at $14 and on 10/18/18 “Upgrades” the stock to Outperform. Furthermore on 6/07/18 “Downgrades” the stock to Sector Perform at $5.

On the other hand the company has Relative Strength Index (RSI 14) of 25.25 along with Average True Range (ATR 14) of 0.08, Consequently Proteostasis Ther Cmn (NASDAQ:PTI)’s weekly and monthly volatility is 8.33%, 6.87% respectively. The company’s beta value is at 0.

In terms of Buy, Sell or Hold recommendations, Proteostasis Ther Cmn (NASDAQ:PTI) has analysts’ mean recommendation of 1.8. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.

According to analysts Proteostasis Ther Cmn (NASDAQ:PTI)’s minimum EPS for the current quarter is at $-0.43 and can go high up to $-0.35. The consensus mean EPS for the current quarter is at $-0.39 derived from a total of 4 estimates from the analysts who have weighed in on projected earnings. However the company reported $-0.43 earnings per share for the same quarter during last year.

Previously Proteostasis Ther Cmn (NASDAQ:PTI) reported $-0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $-0.39 by $0.11. The company posted an earnings surprise of 28.2%.

Currently Proteostasis Ther Cmn (NASDAQ:PTI)’s shares owned by insiders are 0.3%, whereas shares owned by institutional owners are 78.5%. However the six-month change in the insider ownership was recorded -23.15%, as well as three-month change in the institutional ownership was recorded -2.1%.

Proteostasis Ther Cmn (NASDAQ:PTI)’s trailing twelve month revenues are $6.9 Million, whereas its price to sales ratio for the same period is 7.99. Its book value per share for the most recent quarter is $1.98 while its price to book ratio for the same period is 0.53, as for as the company’s cash per share for the most recent quarter is $2.01, however its price to cash per share ratio for the same period is 0.52. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.